New migraine drug tested on 3,000 patients in Real-Life settings
NCT ID NCT06439628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well Rimegepant works for treating migraine attacks in everyday life. About 3,000 adults with migraine will take the drug as prescribed by their doctor and report their pain levels, relief timing, and satisfaction. The goal is to see if Rimegepant helps reduce pain and improve daily function over 12 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhenjiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?